GM, Novo Nordisk, Moderna, Marvell, CrowdStrike

Down 39%. Is Novo Nordisk Stock a Buy on the Dip?
Despite falling hard since last summer, shares of Novo Nordisk have more than doubled the market's overall performance. The stock is up by about 191% over the past five years compared to a 94% gain from the benchmark S&P 500 index.
Hims Stock Claws Back After Novo Nordisk Undercuts It With A Cheaper Wegovy
Novo Nordisk slashed the price of Wegovy by more than half on Wednesday amid a bitter rivalry with Hims & Hers Health.
GM, Novo Nordisk, Moderna, Marvell, CrowdStrike: Stocks to watch today
U.S. stocks reversed early gains and fell around noon after a weak jobs report and concerns over stagflation. At noon in New York, the S&P 500 dipped 0.57%, while the Nasdaq 100 dropped 0.68%. The Dow Jones Industrial Average shed 0.
Why Novo Nordisk Stock Outpaced the Market Today and Hims & Hers Lagged It
Novo Nordisk's (NYSE: NVO) latest move in the retail sphere was met with approval from market participants Wednesday. They bid the stock up by nearly 4% following the company's news, a performance that easily beat the recovering S&P 500's (SNPINDEX: ^GSPC) 1.
Novo Nordisk Plunges 21% in 3 Months: Buy, Sell or Hold the Stock?
Novo Nordisk NVO shares have lost 21% in the past three months against the industry’s growth of 4.6%. The company has also underperformed in the sector and the S&P 500 during the same time frame, as seen in the chart below.
USA Today12d
Shortage of popular drugs Wegovy and Ozempic is over, FDA says.
The Food and Drug Administration on Friday said the shortage of Novo Nordisk's weight-loss and diabetes drugs Wegovy and Ozempic is resolved, a move that could limit the availability of cheaper ...
Novo Nordisk Launches National "My Ozempic® Era" Campaign Celebrating Stories of Inspirational Ozempic® Patients
Novo Nordisk launched "My Ozempic® Era" today, a national campaign which spotlights the longstanding Ozempic® patient ...
Shortage of Novo Nordisk's Wegovy and Ozempic drugs is resolved, FDA says
The FDA’s decision will threaten the ability of compounding pharmacies to make far cheaper, unbranded versions of the ...
Novo Nordisk Joins Legal Battle Over Weight Loss Drug Shortage
Novo Nordisk A/S can intervene in a lawsuit between the FDA and drug compounders over whether its blockbuster drugs Wegovy ...
Newser on MSN4d
FDA Change on Ozempic to Shake Up the Market
The shortage of Ozempic and Wegovy has been declared over by the Food and Drug Administration, a change that suggests higher ...